{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:20:23Z","timestamp":1789647623071,"version":"4.0.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["422640\/2018-2"],"award-info":[{"award-number":["422640\/2018-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/200.656\/2021"],"award-info":[{"award-number":["E-26\/200.656\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/202.734\/2019"],"award-info":[{"award-number":["E-26\/202.734\/2019"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008331","name":"Universidade Federal do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88882.425588\/2019-01"],"award-info":[{"award-number":["88882.425588\/2019-01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejpb.2023.07.016","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T04:05:27Z","timestamp":1690517127000},"page":"184-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vivo evaluation of time-dependent antithrombotic effect of rivaroxaban-loaded poly(lactic-co-glycolic acid)\/sodium lauryl sulfate or didodecyl dimethylammonium bromide nanoparticles in Wistar rats"],"prefix":"10.1016","volume":"190","author":[{"given":"Priscila","family":"de Souza Furtado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Agnes Silva Camargo de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pryscila","family":"Santiago Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rita Santiago de Paula Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Raphaella Autran Cola\u00e7o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pinheiro da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Muniz da Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Wetler Meireles Carreiros Assump\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Pereira Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-6182","authenticated-orcid":false,"given":"Alice","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via","family":"Almada do Carmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Mendes Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pl\u00ednio","family":"Cunha Sathler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpb.2023.07.016_b0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejpb.2023.07.016_b0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mayocp.2020.10.031","article-title":"Coronavirus disease 2019\u2013associated coagulopathy","volume":"96","author":"Lippi","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejpb.2023.07.016_b0015","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/crj.13438","article-title":"COVID-19 and coagulopathy","volume":"15","author":"Sarkar","year":"2021","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.ejpb.2023.07.016_b0020","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.3390\/ijms23158283","article-title":"The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V","volume":"23","author":"Pablo-Moreno","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.07.016_b0025","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00011-020-01401-6","article-title":"The coagulopathy, endotheliopathy, and vasculitis of COVID-19","volume":"69","author":"Iba","year":"2020","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejpb.2023.07.016_b0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/ALN.0000000000004239","article-title":"Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study","volume":"137","author":"Corey","year":"2022","journal-title":"Anesthesiology."},{"key":"10.1016\/j.ejpb.2023.07.016_b0035","series-title":"StatPearls [Internet]","article-title":"Virchow triad","author":"Kushner","year":"2022"},{"key":"10.1016\/j.ejpb.2023.07.016_b0040","doi-asserted-by":"crossref","first-page":"9317","DOI":"10.3390\/ijms22179317","article-title":"Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence","volume":"22","author":"Zifkos","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.07.016_b0045","first-page":"1","article-title":"The Effect of Extracellular Vesicles on Thrombosis","volume":"2022","author":"He","year":"2022","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.ejpb.2023.07.016_b0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/stresses3010013","article-title":"Gender Medicine: A New Possible Frontiers of Venous Thromboembolism","volume":"3","author":"Ciarambino","year":"2023","journal-title":"Stresses."},{"key":"10.1016\/j.ejpb.2023.07.016_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111978","article-title":"Development of rivaroxaban microemulsion-based hydrogel for transdermal treatment and prevention of venous thromboembolism","volume":"206","author":"Ara\u00fajo","year":"2021","journal-title":"Colloids Surf B Biointerfaces."},{"key":"10.1016\/j.ejpb.2023.07.016_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/applnano2020009","article-title":"Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems","volume":"2","author":"Patriota","year":"2021","journal-title":"Applied Nano"},{"key":"10.1016\/j.ejpb.2023.07.016_b0065","unstructured":"S. Patel, R. Singh, C. V Preuss, N. Patel, Warfarin, StatPearls [Internet]. (2021)."},{"key":"10.1016\/j.ejpb.2023.07.016_b0070","first-page":"175","article-title":"The evolution of anticoagulant therapy","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus."},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct oral anticoagulants: a quick guide","volume":"12","author":"Sikorska","year":"2017","journal-title":"European Cardiology Review."},{"key":"10.1016\/j.ejpb.2023.07.016_b0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/09674845.2019.1605648","article-title":"The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban","volume":"76","author":"Kim","year":"2019","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.ejpb.2023.07.016_b0085","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/abd0b5","article-title":"Novel rivaroxaban\u2014loaded poly (lactic-co-glycolic acid)\/poloxamer nanoparticles: preparation, physicochemical characterization, in vitro evaluation of time-dependent anticoagulant activity and toxicological profile","volume":"32","author":"Machado","year":"2021","journal-title":"Nanotechnology."},{"key":"10.1016\/j.ejpb.2023.07.016_b0090","first-page":"202","article-title":"Pharmaceutical nanotechnology and application","volume":"9","author":"Khidir","year":"2020","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.07.016_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-813586-0.00001-8","article-title":"An Introduction to Nanotechnology","volume":"28","author":"Nasrollahzadeh","year":"2019","journal-title":"Interface Science and Technology."},{"key":"10.1016\/j.ejpb.2023.07.016_b0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-4614-8993-1_14","article-title":"Polymeric nanoparticles: in vivo toxicological evaluation, cardiotoxicity, and hepatotoxicity","author":"Garcia","year":"2014","journal-title":"Nanotoxicology: Materials, Methodologies, and Assessments"},{"key":"10.1016\/j.ejpb.2023.07.016_b0105","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1590\/S0100-40422013001000007","article-title":"Impactos da nanotecnologia na sa\u00fade: produ\u00e7\u00e3o de medicamentos","volume":"36","author":"Dimer","year":"2013","journal-title":"Quim Nova"},{"key":"10.1016\/j.ejpb.2023.07.016_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nanoso.2019.100397","article-title":"Recent developments in functionalized polymer nanoparticles for efficient drug delivery system","volume":"20","author":"Sur","year":"2019","journal-title":"Nano-Structures & Nano-Objects."},{"key":"10.1016\/j.ejpb.2023.07.016_b0115","doi-asserted-by":"crossref","first-page":"32004","DOI":"10.1088\/2632-959X\/abcca6","article-title":"Microfluidic devices for synthesizing nanomaterials\u2014A review","volume":"1","author":"Kulkarni","year":"2020","journal-title":"Nano Express."},{"key":"10.1016\/j.ejpb.2023.07.016_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/3702518","article-title":"Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine","volume":"2019","author":"Lombardo","year":"2019","journal-title":"J. Nanomater."},{"issue":"3","key":"10.1016\/j.ejpb.2023.07.016_b0125","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1590\/S1517-70762006000300024","article-title":"S\u00edntese, caracteriza\u00e7\u00e3o e degrada\u00e7\u00e3o\u201c in vitro\u201d do poli (L-\u00e1cido l\u00e1ctico-co-\u00e1cido glic\u00f3lico)","volume":"11","author":"Motta","year":"2006","journal-title":"Mat\u00e9ria (Rio de Janeiro)."},{"issue":"6","key":"10.1016\/j.ejpb.2023.07.016_b0130","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/jps.21124","article-title":"Effect of structural relaxation on the preparation and drug release behavior of poly (lactic-co-glycolic) acid microparticle drug delivery systems","volume":"97","author":"Allison","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.07.016_b0135","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (Basel)."},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jps.21082","article-title":"Engineering biodegradable polyester particles with specific drug targeting and drug release properties","volume":"97","author":"Mohamed","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2023.07.016_b0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.07.016_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.surfrep.2017.02.001","article-title":"Nanoparticle decoration with surfactants: molecular interactions, assembly, and applications","volume":"72","author":"Heinz","year":"2017","journal-title":"Surf. Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.07.016_b0155","first-page":"404","article-title":"Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant study, Asian","volume":"11","author":"Sharma","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2023.07.016_b0160","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1590\/S0100-40422003000500017","article-title":"Caracteriza\u00e7\u00e3o e estabilidade f\u00edsico-qu\u00edmica de sistemas polim\u00e9ricos nanoparticulados para administra\u00e7\u00e3o de f\u00e1rmacos","volume":"26","author":"Schaffazick","year":"2003","journal-title":"Quim Nova"},{"key":"10.1016\/j.ejpb.2023.07.016_b0165","first-page":"255","article-title":"Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1)","volume":"12","author":"Honary","year":"2013","journal-title":"Trop. J. Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejpb.2023.07.016_b0170","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.ejpb.2023.07.016_b0175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0142-9612(02)00440-4","article-title":"Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating","volume":"24","author":"Wilhelm","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.07.016_b0180","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jddst.2017.11.002","article-title":"Didodecyldimethylammonium bromide (DMAB) stabilized poly (lactic-co-glycolic acid)(PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells","volume":"43","author":"Gossmann","year":"2018","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.ejpb.2023.07.016_b0185","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/aaae5b","article-title":"A promising oral fucoidan-based antithrombotic nanosystem: development, activity and safety","volume":"29","author":"da Silva","year":"2018","journal-title":"Nanotechnology."},{"issue":"4","key":"10.1016\/j.ejpb.2023.07.016_b0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/10837450.2017.1290107","article-title":"Development and characterization of poly (lactic-co-glycolic) acid nanoparticles loaded with copaiba oleoresin","volume":"23","author":"de Almeida Borges","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2023.07.016_b0195","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.thromres.2014.05.009","article-title":"In vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems: determination of novel NAH derivatives antiplatelet and nanotechnological approach","volume":"134","author":"Sathler","year":"2014","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.ejpb.2023.07.016_b0200","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1208\/s12249-016-0477-3","article-title":"Development and characterization of nisin nanoparticles as potential alternative for the recurrent vaginal candidiasis treatment","volume":"17","author":"de Abreu","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2023.07.016_b0205","article-title":"Benign prostatic hyperplasia therapy through liquisolid technology composed of polymer-layered nanocomposites based on silicate that contain babassu oil and copaiba oil-resin","volume":"64","author":"de Souza Furtado","year":"2021","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.ejpb.2023.07.016_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121841","article-title":"Therapeutic implementation in arterial thrombosis with pulmonary administration of fucoidan microparticles containing acetylsalicylic acid","volume":"622","author":"Saito","year":"2022","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.ejpb.2023.07.016_b0215","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11239-019-02022-5","article-title":"Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect","volume":"49","author":"Anwer","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ejpb.2023.07.016_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-01836-4","article-title":"Nanodelivery of Resveratrol-Loaded PLGA Nanoparticles for Age-Related Macular Degeneration","volume":"21","author":"Bhatt","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2023.07.016_b0225","unstructured":"ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Text and Methodology, Q2(R1), 2005."},{"issue":"4","key":"10.1016\/j.ejpb.2023.07.016_b0230","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1081\/DDC-100102197","article-title":"Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method","volume":"25","author":"Barichello","year":"1999","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2023.07.016_b0235","first-page":"359","article-title":"RP-HPLC method development and validation for estimation of rivaroxaban in pharmaceutical dosage forms, Brazilian","volume":"49","author":"\u00c7elebier","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2023.07.016_b0240","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jpba.2007.10.030","article-title":"Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound","volume":"46","author":"Baka","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1208\/s12249-017-0811-4","article-title":"Design and development of repaglinide microemulsion gel for transdermal delivery","volume":"19","author":"Shinde","year":"2018","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0250","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2016.08.052","article-title":"Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation","volume":"512","author":"Simon","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2023.07.016_b0255","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1208\/s12249-013-9960-2","article-title":"Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions","volume":"14","author":"Liu","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2023.07.016_b0260","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ab373e","article-title":"Oral pentamidine-loaded poly (d, l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment","volume":"30","author":"Valle","year":"2019","journal-title":"Nanotechnology."},{"issue":"2","key":"10.1016\/j.ejpb.2023.07.016_b0265","doi-asserted-by":"crossref","first-page":"e03451","DOI":"10.1016\/j.heliyon.2020.e03451","article-title":"A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles","volume":"6","author":"Pourtalebi Jahromi","year":"2020","journal-title":"Heliyon."},{"key":"10.1016\/j.ejpb.2023.07.016_b0270","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/pharmaceutics11040184","article-title":"Design of poly (lactic-co-glycolic acid)(PLGA) nanoparticles for vaginal co-delivery of griffithsin and dapivirine and their synergistic effect for HIV prophylaxis","volume":"11","author":"Yang","year":"2019","journal-title":"Pharmaceutics."},{"issue":"04","key":"10.1016\/j.ejpb.2023.07.016_b0275","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1160\/TH16-09-0694","article-title":"Improved anticoagulant effect of fucosylated chondroitin sulfate orally administered as gastroresistant tablets","volume":"117","author":"Fonseca","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejpb.2023.07.016_b0280","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/jphp.12771","article-title":"The antithrombotic and haemostatic effects of LASSB io-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats","volume":"69","author":"Frattani","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"1-2","key":"10.1016\/j.ejpb.2023.07.016_b0285","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijbiomac.2004.12.002","article-title":"Anticoagulant and antithrombotic activities of a chemically sulfated galactoglucomannan obtained from the lichen Cladonia ibitipocae","volume":"35","author":"Martinichen-Herrero","year":"2005","journal-title":"Int. J. Biol. Macromol."},{"issue":"07","key":"10.1016\/j.ejpb.2023.07.016_b0290","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejpb.2023.07.016_b0295","article-title":"Oral antithrombotic effects of acylhydrazone derivatives","volume":"14886","author":"Frattani","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"issue":"7","key":"10.1016\/j.ejpb.2023.07.016_b0300","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/mabi.201200017","article-title":"Poly (2-ethyl-2-oxazoline) as Alternative for the Stealth Polymer Poly (ethylene glycol): Comparison of in vitro Cytotoxicity and Hemocompatibility","volume":"12","author":"Bauer","year":"2012","journal-title":"Macromol. Biosci."},{"issue":"1-3","key":"10.1016\/j.ejpb.2023.07.016_b0305","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0009-3084(93)90070-J","article-title":"Toxicity screening of liposomes","volume":"64","author":"Parnham","year":"1993","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.ejpb.2023.07.016_b0310","unstructured":"F. ASTM, F756-08, Standard Practice for Assessment of Hemolytic Properties of Materials,\u201d ASTM International, West Conshohocken, PA, ASTM Book of Standards. (2013)."},{"key":"10.1016\/j.ejpb.2023.07.016_b0315","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3109\/14756366.2016.1158712","article-title":"Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization","volume":"31","author":"Saito","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0320","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41551-019-0465-5","article-title":"Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability","volume":"4","author":"Lamson","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ejpb.2023.07.016_b0325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jconrel.2007.02.004","article-title":"PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral\u00ae","volume":"119","author":"Italia","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.07.016_b0330","first-page":"1882","article-title":"A review of biodegradable polymeric systems for oral insulin delivery","volume":"23","author":"Luo","year":"2016","journal-title":"Drug Deliv."},{"issue":"9","key":"10.1016\/j.ejpb.2023.07.016_b0335","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/17425247.2015.1018175","article-title":"Polymeric nanoparticle drug delivery technologies for oral delivery applications","volume":"12","author":"Pridgen","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0340","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.fshw.2019.12.003","article-title":"The interaction of nanostructured antimicrobials with biological systems: Cellular uptake, trafficking and potential toxicity","volume":"9","author":"Brandelli","year":"2020","journal-title":"Food Sci. Human Wellness"},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","article-title":"Nanoparticles for drug delivery: the need for precision in reporting particle size parameters","volume":"69","author":"Gaumet","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.07.016_b0350","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.msec.2015.08.062","article-title":"Synthesis and characterization of the antitubercular phenazine lapazine and development of PLGA and PCL nanoparticles for its entrapment","volume":"58","author":"Silveira","year":"2016","journal-title":"Mater. Sci. Eng. C."},{"key":"10.1016\/j.ejpb.2023.07.016_b0355","doi-asserted-by":"crossref","first-page":"101907","DOI":"10.1016\/j.jddst.2020.101907","article-title":"Preparation of PDLLA and PLGA nanoparticles stabilized with PVA and a PVA-SDS mixture: studies on particle size, degradation and drug release during storage","volume":"60","author":"Ramirez","year":"2020","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.ejpb.2023.07.016_b0360","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcis.2019.08.060","article-title":"Synthetic and biological identities of polymeric nanoparticles influencing the cellular delivery: An immunological link","volume":"556","author":"Rezaei","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2023.07.016_b0365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1071\/CH19359","article-title":"Microfluidic synthesis of rifampicin loaded PLGA nanoparticles and the effect of formulation on their physical and antibacterial properties","volume":"73","author":"Meikle","year":"2020","journal-title":"Aust. J. Chem."},{"key":"10.1016\/j.ejpb.2023.07.016_b0370","doi-asserted-by":"crossref","first-page":"109818","DOI":"10.1016\/j.eurpolymj.2020.109818","article-title":"Formulation, physico-chemical characterization and antidiabetic potential of naringenin-loaded poly D, L lactide-co-glycolide (N-PLGA) nanoparticles","volume":"134","author":"Maity","year":"2020","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.ejpb.2023.07.016_b0375","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2018.02.045","article-title":"Oral insulin delivery, the challenge to increase insulin bioavailability: Influence of surface charge in nanoparticle system","volume":"542","author":"Czuba","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.07.016_b0380","first-page":"172","article-title":"Characterization of Self-Microemulsifying Dosage Form: Special Emphasis on Zeta Potential Measurement","volume":"10","author":"Kulkarni","year":"2019","journal-title":"Int J Pharm Biol Arch."},{"key":"10.1016\/j.ejpb.2023.07.016_b0385","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2147\/IJN.S130908","article-title":"Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis","volume":"12","author":"Marcianes","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.07.016_b0390","series-title":"Nanomaterials for Drug Delivery and Therapy","first-page":"91","author":"Joseph","year":"2019"},{"key":"10.1016\/j.ejpb.2023.07.016_b0395","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.msec.2016.01.084","article-title":"Spray dried microspheres based on chitosan: a promising new carrier for intranasal administration of polymeric antigen BLSOmp31 for prevention of ovine brucellosis","volume":"62","author":"D\u00edaz","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"issue":"12","key":"10.1016\/j.ejpb.2023.07.016_b0400","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jsps.2020.11.012","article-title":"Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability","volume":"28","author":"Faris","year":"2020","journal-title":"Saudi Pharmaceutical Journal."},{"key":"10.1016\/j.ejpb.2023.07.016_b0405","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/03601234.2019.1634971","article-title":"Controlled-release of fluazinam from biodegradable PLGA-based microspheres","volume":"54","author":"Wang","year":"2019","journal-title":"J. Environ. Sci. Health B"},{"key":"10.1016\/j.ejpb.2023.07.016_b0410","first-page":"3977","article-title":"Formulation and in vitro evaluation of niacin-loaded nanoparticles to reduce prostaglandin mediated vasodilatory flushing","volume":"19","author":"Cooper","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejpb.2023.07.016_b0415","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ab97d7","article-title":"Vancomycin-loaded nanoparticles against vancomycin intermediate and methicillin resistant Staphylococcus aureus strains","volume":"31","author":"Simon","year":"2020","journal-title":"Nanotechnology."},{"issue":"6","key":"10.1016\/j.ejpb.2023.07.016_b0420","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1039\/C8MH01527A","article-title":"Non-spherical micro-and nanoparticles in nanomedicine","volume":"6","author":"Zhu","year":"2019","journal-title":"Mater. Horiz."},{"key":"10.1016\/j.ejpb.2023.07.016_b0425","first-page":"5793","article-title":"Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies","volume":"7","author":"Mart\u00edn-Banderas","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.07.016_b0430","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2017.08.064","article-title":"Nanoprecipitation process: From encapsulation to drug delivery","volume":"532","author":"Rivas","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.07.016_b0435","series-title":"Polymer Nanoparticles for Nanomedicines","first-page":"17","article-title":"Nanoprecipitation process: from particle preparation to in vivo applications","author":"Miladi","year":"2016"},{"key":"10.1016\/j.ejpb.2023.07.016_b0440","first-page":"95","article-title":"Fate and effects of the surfactant sodium dodecyl sulfate","author":"Singer","year":"1993","journal-title":"Reviews of Environmental Contamination and Toxicology: Continuation of Residue Reviews"},{"key":"10.1016\/j.ejpb.2023.07.016_b0445","series-title":"United States Pharmacopeia and National Formulary (USP 37\u2013NF 32), Rockville","author":"Pharmacopeia","year":"2014"},{"key":"10.1016\/j.ejpb.2023.07.016_b0450","series-title":"Lipid and Polymer-Lipid Systems","first-page":"83","article-title":"Effect of a bile salt on the aggregation behavior of a double-chained cationic surfactant-the cationic-rich dilute region of the didodecyldimethylammonium bromide-sodium taurodeoxycholate-water system","author":"Marques","year":"2002"},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0455","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijpharm.2016.08.062","article-title":"Solubilization and formulation of chrysosplenol C in solid dispersion with hydrophilic carriers","volume":"512","author":"Ng","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2023.07.016_b0460","doi-asserted-by":"crossref","first-page":"103987","DOI":"10.1016\/j.jece.2020.103987","article-title":"Thomas, Effect of surface charge and other critical parameters on the adsorption of dyes on SLS coated ZnO nanoparticles and optimization using response surface methodology","volume":"8","author":"Pinheiro","year":"2020","journal-title":"J. Environ. Chem. Eng."},{"issue":"4","key":"10.1016\/j.ejpb.2023.07.016_b0465","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1208\/s12249-018-0991-6","article-title":"Preparation and Optimization of Rivaroxaban by Self-Nanoemulsifying Drug Delivery System (SNEDDS) for Enhanced Oral Bioavailability and No Food Effect","volume":"19","author":"Xue","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2023.07.016_b0470","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rb\/rbx026","article-title":"Synthesis and characterization of collagen\/PLGA biodegradable skin scaffold fibers","volume":"4","author":"Sadeghi-Avalshahr","year":"2017","journal-title":"Regen Biomater."},{"key":"10.1016\/j.ejpb.2023.07.016_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics5010001","article-title":"Efavirenz dissolution enhancement I: co-micronization","volume":"5","author":"Da Costa","year":"2013","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2023.07.016_b0480","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1021\/la052822l","article-title":"Didodecyldimethylammonium bromide lipid bilayer-protected gold nanoparticles: synthesis, characterization, and self-assembly","volume":"22","author":"Zhang","year":"2006","journal-title":"Langmuir"},{"key":"10.1016\/j.ejpb.2023.07.016_b0485","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1590\/S1516-93322006000400007","article-title":"Thermoanalytical study of praziquantel-loaded PLGA nanoparticles","volume":"42","author":"Mainardes","year":"2006","journal-title":"Revista Brasileira de Ci\u00eancias Farmac\u00eauticas."},{"key":"10.1016\/j.ejpb.2023.07.016_b0490","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10973-012-2580-3","article-title":"Structural and thermal properties of spray-dried methotrexate-loaded biodegradable microparticles","volume":"112","author":"De Oliveira","year":"2013","journal-title":"J. Therm. Anal. Calorim."},{"issue":"3","key":"10.1016\/j.ejpb.2023.07.016_b0495","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s10973-017-6412-3","article-title":"Compatibility study of rivaroxaban and its pharmaceutical excipients","volume":"130","author":"Ding","year":"2017","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejpb.2023.07.016_b0500","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.181457","article-title":"Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy","volume":"5","author":"Wan","year":"2018","journal-title":"R. Soc. Open Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2023.07.016_b0505","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jconrel.2013.05.034","article-title":"The effect of lauryl capping group on protein release and degradation of poly (d, l-lactic-co-glycolic acid) particles","volume":"172","author":"Samadi","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.07.016_b0510","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/polym11111905","article-title":"Transferrin-Conjugated Docetaxel\u2013PLGA Nanoparticles for Tumor Targeting: Influence on MCF-7 Cell Cycle","volume":"11","author":"Jose","year":"2019","journal-title":"Polymers (Basel)."},{"issue":"3","key":"10.1016\/j.ejpb.2023.07.016_b0515","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jconrel.2006.06.011","article-title":"Uptake studies in rat Peyer\u2019s patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination","volume":"114","author":"Borges","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.07.016_b0520","first-page":"19670","article-title":"Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer","volume":"8","author":"Sun","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ejpb.2023.07.016_b0525","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1590\/S1516-93322005000200003","article-title":"Formas farmac\u00eauticas de libera\u00e7\u00e3o modificada: pol\u00edmeros hidrif\u00edlicos","volume":"41","author":"Lopes","year":"2005","journal-title":"Revista Brasileira de Ci\u00eancias Farmac\u00eauticas."},{"key":"10.1016\/j.ejpb.2023.07.016_b0530","doi-asserted-by":"crossref","first-page":"122","DOI":"10.36660\/ijcs.20200373","article-title":"Rivaroxaban: is it Really Need to Monitor its Anticoagulant Effect in Clinical Practice?","volume":"34","author":"Camanho","year":"2021","journal-title":"International Journal of Cardiovascular Sciences."},{"key":"10.1016\/j.ejpb.2023.07.016_b0535","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/phar.1884","article-title":"Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know","volume":"37","author":"Conway","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejpb.2023.07.016_b0540","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.ejpb.2023.07.016_b0545","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2014an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.ejpb.2023.07.016_b0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2023.07.016_b0555","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0142-9612(02)00445-3","article-title":"In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis","volume":"24","author":"Fischer","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.07.016_b0560","unstructured":"ISO, 10993\u20135 2009 Biological Evaluation of Medical Devices\u2014Part 5: Tests for in vitro Cytotoxicity Geneva, 2009."},{"issue":"7","key":"10.1016\/j.ejpb.2023.07.016_b0565","doi-asserted-by":"crossref","first-page":"e0127532","DOI":"10.1371\/journal.pone.0127532","article-title":"New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly (lactic-co-glycolic acid)(PLGA) nanoparticles","volume":"10","author":"Gossmann","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.07.016_b0570","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.toxrep.2019.07.006","article-title":"Subacute toxicity study of aqueous root extract of Terminalia schimperiana in male Wistar rats","volume":"6","author":"Awotunde","year":"2019","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.ejpb.2023.07.016_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/8839898","article-title":"Protective effect of thyme honey against valproic acid hepatotoxicity in Wistar Rats","volume":"2021","author":"Omidipour","year":"2021","journal-title":"Biomed Res. Int."},{"issue":"8","key":"10.1016\/j.ejpb.2023.07.016_b0580","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-015-0317-5","article-title":"Hepatotoxicity of new oral anticoagulants (NOACs)","volume":"38","author":"Liakoni","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejpb.2023.07.016_b0585","first-page":"1683","article-title":"Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban, JAMA","volume":"174","author":"Liakoni","year":"2014","journal-title":"Intern. Med."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:01Z","timestamp":1760547241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123001984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":117,"alternative-id":["S0939641123001984"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.07.016","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo evaluation of time-dependent antithrombotic effect of rivaroxaban-loaded poly(lactic-co-glycolic acid)\/sodium lauryl sulfate or didodecyl dimethylammonium bromide nanoparticles in Wistar rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}